MMR Deficiency in Colorectal Cancer: Testing, Meaning and Treatment

Mismatch repair (MMR) deficiency is a molecular hallmark that reflects a tumor’s compromised ability to rectify DNA copying mistakes during cell division. Assessing the MMR status has become a critical standard in the diagnostic workflow for colorectal cancer, as it bears essential implications for identifying Lynch syndrome and shaping treatment strategies, including the use of targeted immunotherapies in specific patient subsets.

MMR deficiency refers to a state where the tumor’s mechanism for correcting errors—specifically base-pair mismatches or minor DNA insertions and deletions—is faulty or inactive. Cancers exhibiting this deficiency are labeled as dMMR (deficient mismatch repair).

In such tumors, the failure to fix DNA replication errors leads to their accumulation, especially in repetitive DNA regions known as microsatellites. This buildup results in a separate, yet related, molecular phenomenon termed microsatellite instability (MSI). Testing for MMR in colorectal cancer allows clinicians to classify tumors as either MMR-deficient or MMR-proficient, a distinction pivotal for assessing hereditary cancer risk and informing personalized treatment plans.

At its core, the mismatch repair system functions as a guardian of genetic fidelity, correcting the small slips that occur during DNA replication. The principal proteins supporting this process are MLH1, MSH2, MSH6, and PMS2. Working in unison, they recognize the erroneous DNA, excise the flawed segment, and mend the sequence to preserve normal cellular function.

Loss or malfunction of any of these proteins results in unchecked DNA errors, which, over time, drive the accumulation of mutations and contribute to the initiation and progression of cancer.

MMR deficiency may have genetic or acquired origins. Hereditary cases often involve pathogenic variants in core MMR genes—MLH1, MSH2, MSH6, PMS2, or EPCAM—and are closely tied to Lynch syndrome. On the other hand, non-inherited mechanisms can include epigenetic silencing (such as MLH1 promoter hypermethylation), somatic mutations of MMR genes, or other tumor-specific molecular events. Thus, MMR deficiency might arise without any hereditary risk, and its detection serves as a gateway to further evaluation—not an immediate diagnosis of Lynch syndrome.

Immunohistochemistry (IHC):
The most common approach to testing MMR status is IHC, which utilizes labeled antibodies to detect the presence (or absence) of the four main MMR proteins within tumor cells. Loss of staining for any of these proteins suggests dMMR. The specific pattern of protein loss can offer hints about the underlying defect, guiding further testing—such as MLH1 promoter hypermethylation or BRAF V600E mutation analysis—to discriminate between sporadic and hereditary origins.

Molecular MSI Testing:
An alternative is MSI testing, which investigates whether microsatellite regions exhibit abnormal variability—a sign of underlying repair deficits. While both IHC and MSI testing probe the MMR pathway, they do so via different methodologies; IHC measures protein expression, while MSI examines the stability of repetitive DNA regions. Advanced next-generation sequencing (NGS) platforms can also provide validated MSI assessments.

The functional status of MMR is more than a laboratory label—it profoundly impacts disease behavior and management. dMMR tumors tend to have a higher load of mutations and may display a unique clinical course or enhanced responsiveness to certain treatments like immunotherapy, particularly in the advanced or metastatic setting. In contrast, pMMR cancers retain a normal repair capacity and often follow different therapeutic pathways.

Although MMR deficiency and MSI-H (microsatellite instability-high) are closely intertwined, they are not linguistically or biologically interchangeable. While dMMR pinpoints impaired protein function, MSI-H specifically refers to extensive instability in microsatellite regions. Frequently, dMMR leads to MSI-H, and together, they are often summarized as dMMR/MSI-H tumors in clinical literature, though their assessments derive from separate test platforms.

The presence of MMR deficiency increasingly guides therapeutic decisions. In advanced disease, dMMR/MSI-H tumors, with their abundant mutated proteins, can be targeted effectively by immune checkpoint inhibitors. For example, pembrolizumab has gained approval for various unresectable or metastatic MSI-H/dMMR solid tumors after standard options have failed, showing longer progression-free survival than traditional chemotherapy in some trials.

Nonetheless, treatment is multifactorial and tailored to the patient—considering not only MMR status, but also factors such as tumor site, molecular features (e.g., RAS, BRAF, HER2 status), previous interventions, and overall patient health.

A finding of MMR deficiency often triggers in-depth evaluation for Lynch syndrome, especially for patients with suggestive family or personal cancer histories. Additional testing—such as evaluation for MLH1 methylation, BRAF mutations, somatic profiling, and germline genetic analysis—aids in distinguishing between inherited versus sporadic MMR deficiency, providing clarity around cancer risk for both the patient and their family.